#### SPONSORSHIP AGREEMENT

This sponsorship agreement (the "Agreement") is made effective as of 23. March 2022 (the "Effective Date"), between Swedish Orphan Biovitrum A/S, Sorgenfrivej 17, 2800 Lyngby ("Sobi") and Danmarks Bløderforening ("Recipient").

WHEREAS, Sobi A/S is an affiliate of an international biopharmaceutical company dedicated to rare diseases:

WHEREAS, Recipient is Danmarks Bløderforening; and

WHEREAS, Sobi has agreed to sponsor Danmarks Bløderforening Forsknings- og Støttefond (the "Meeting") on the terms and conditions set out below.

NOW, THEREFORE, the parties agree as follows:

#### 1. TERMS AND CONDITIONS OF SPONSORSHIP

- 1.1 **Sponsorship:** Sobi hereby agrees to provide Recipient the sum of 4.000 DKK + applicable VAT for the purpose of (the "Sponsorship").
- 1.2 Scope: The Sponsorship shall only cover actual, documented, reasonable and direct costs that are necessary in order to carry out the professional parts of the Meeting, as further specified in <u>Schedule 1</u>. Activities and materials generated as a result of this Sponsorship shall comply with all applicable laws and regulations.
- 1.3 Meeting Budget and Repayment: Recipient have provided Sobi with a complete budget for the Meeting. Unused budget resources shall be repaid to Sobi without delay after the Meeting or immediately if the Meeting is cancelled.
- 1.4 **Benefits of Sponsorship:** In return for Sobi sponsoring the Meeting Recipient shall provide Sobi with the benefits specified in Schedule 2.
- 1.5 **Payment:** The Sponsorship will be paid in the following instalments..
- 1.6 Payment Terms: All payments hereunder shall be made within thirty (30) days via bank transfer or from receipt of invoice provided that the following conditions shall have been met: invoices shall be specified as to Sobi contact person Julie Trolle. Sobi's invoice address is: Sobi, Sorgenfrivej 17, 2800 Lyngby.
  - Sobi shall pay Recipient by electronic bank transfer in accordance with the above agreed payment schedule.

- 1.7 **Communication:** Well before the Meeting, Recipient shall communicate the names of all sponsors. Sobi will be transparent regarding its support of the Meeting and the Recipient agrees to be similarly transparent. The Sponsorship will be acknowledged by the Recipient and made clear on all materials as further specified in <a href="Schedule 2">Schedule 2</a>. Participants' invitations shall state the Recipient as the organizer, the purpose of the Meeting activities and identify as sponsors Sobi and any other pharmaceutical companies which sponsor the Meeting
- 1.8 **Use of Sobi name:** Recipient shall only use the name and logotypes of Sobi, in publications, presentations, programmes, other printed or orally presented materials or otherwise, after prior review and approval of Sobi.
- 1.9 **No inducement:** Recipient acknowledges that provision of the Sponsorship is in no way an inducement to recommend, prescribe, purchase, supply, sell or administer a particular medicinal product.
- 1.10 **Hospitality, programme and venue of the Meeting**: The Recipient represents and warrants to Sobi that
  - (a) Hospitality made directly or indirectly available during the Meeting shall be kept at a reasonable level and remain secondary to the principal scientific purpose of the Meeting, be limited to the organisation and/or defrayment of the costs of travel, meals, accommodation and registration, shall not extend beyond the official duration of the Meeting and shall not include payment for or the organization of sports or leisure activities or any other form of entertainment;
  - (b) The value of meals provided, drinks included, shall not exceed the limits laid down by Applicable Law, including applicable local industry guidelines;
  - (c) The Meeting shall be predominantly scientific in nature and activities with a scientific purpose shall, in terms of time, take up the greater part of each day of the Meeting; and
  - (d) The Meeting shall take place at a suitable venue that aids the scientific purpose of the event and the place, date and duration of the Meeting and travel shall not in any case be of a nature to create any confusion as to its scientific nature.

#### 2. MISCELLANEOUS PROVISIONS

- 2.1 **Entire Agreement:** This Agreement, including its Schedules, constitutes the entire understanding between the parties with respect to the subject matter hereof and supersedes all prior oral or written agreements of the parties with respect to such subject matter
- 2.2 **Amendments:** No provision of this Agreement may be amended, modified or otherwise changed, other than by an instrument in writing duly executed on behalf of the parties to this Agreement.
- 2.3 **Assignments:** This Agreement is personal to the parties who shall not have any right to assign it without the prior written consent of the other party, except that Sobi shall have the right to assign the Agreement to its affiliates.
- 2.4 **Independent Contractors:** In making and performing this Agreement, the parties are acting and shall act at all times as independent contractors, and nothing contained in this Agreement shall be construed or implied to create any agency, partnership or employer and employee relationship between Sobi and Recipient. At no time shall any party make commitments or incur any charges or expenses for or in the name of any other party, other than as expressly set forth herein.

### 3. PROCESSING OF PERSONAL DATA

- 3.1 The General Data Protection Regulation ("GDPR") requires that Sobi provides Recipient notice of Sobi's processing of personal data about Recipient.
- 3.2 The Sobi entity which is party to this Agreement is data controller for the processing of Recipient's personal data.
- 3.3 Sobi processes the personal data provided by Recipient with a view to administrate this Agreement, including payment of any agreed compensation. The basis for the processing is Article 6(1)(b) of the GDPR as processing of Recipient's personal data is necessary for the performance of this Agreement.
- 3.4 Furthermore, Sobi may store Recipient's contact information in a database for the purpose of engaging Recipient as a future speaker, for meetings and training events and similar services. Sobi may also process Recipient's personal data for internal evaluation purposes. Such processing is based on Article 6(1)(f) of the

- GDPR as Sobi has a legitimate interest in maintaining the relationship with Recipient and improving Sobi's products.
- 3.5 Sobi may also process Recipient's personal data for the dispatch of e-mails regarding upcoming event, invitations, new products, etc. Sobi will obtain Recipient's prior consent, should it be required. In such case, the processing is based on Article 6(1)(a) of the GDPR.
- 3.6 Recipient's name may be published on invitations to the Event. Such processing is based on Article 6(1)(f) of the GDPR as Sobi has a legitimate interest in publishing the content of the Event.
- 3.7 To meet the purposes mentioned above, Sobi may share Recipient's personal data within the Sobi group and with Sobi service providers, e.g. IT system providers, and agents.
- 3.8 Such sharing may include transfer to third countries, i.e. countries outside the EU/EEA area. When transferring Recipient's personal data to third countries, Sobi will ensure that the transfer is subject to appropriate safeguards and that Recipient's rights are protected. Typically, Sobi will enter into standard contractual clauses adopted by the EU Commission with companies in third countries receiving personal data from Sobi.
- 3.9 In general, Sobi deletes Recipient's personal data when Sobi no longer needs them to meet the purposes mentioned above.
- 3.9 As a main rule, Sobi stores personal data on Recipient for a period of 2 years from latest engagement of Recipient or latest communication with Recipient. If Recipient's social security registration number is collected, such data will be deleted after reporting to the relevant government entities/public authorities. Personal data which must be stored under the Danish Bookkeeping Act will be deleted 5 years after the end of the relevant financial year.
- 3.10 The personal data may, however, be processed and kept for a longer period in anonymised form or if Sobi is required to do so by law.
- 3.11 Recipient has the right to access the personal data that Sobi processes concerning the Recipient and to request that Sobi rectifies any inaccurate personal data and under certain circumstances request erasure and/or restriction of processing of the personal data. Recipient has the right to object to processing and to receive the processed personal data in a structured, commonly used and machine-readable format and has the right to transmit those data to another data controller. Provided that Sobi is a legal entity with a registered office in an EU member

state, Recipient also has the right to lodge a complaint to the supervisory authority The Danish Data Protection Agency regarding Sobi's processing of Recipient's personal data.

## 4. GOVERNING LAW AND JURISDICTION

This Agreement shall be governed and construed by the substantive laws of Danmark. Any dispute, controversy or claim arising out of or in connection with this Agreement, or the breach, termination or invalidity thereof, shall be finally settled by the courts of the above said country.

[Signatures to follow on the next page.]

This Agreement has been signed by each party's duly authorized signatory(ies). This Agreement may be executed and transmitted via email in Portable Document Format (PDF), and in counterparts, each of which taken together, shall constitute one agreement binding on the parties with the same force and effect as an original signed agreement.

## **Mai Clifford**

DocuSigned by:

Name: Mai Clifford Title: Country Manager

Date:

Karen Binger Holm

DocuSigned by:

Name: Karen Binger Holm Title: Head of the Secretariat

Date:

#### **SPONSORSHIP AND COSTS**

Sobi will sponsor 4.000 DKK to Danmarks Bløderforening Forsknings- og Støttefond.

Swedish Orphan Biovitrum A/S Att.: Julie Trolle Sorgenfrivej 17 2800 Lyngby

Ansøgning om støtte til Danmarks Bløderforenings Forsknings- og Støttefond Med denne ansøgning søger Danmarks Bløderforening om støtte på i alt 4.000 kr. til foreningens Forsknings- og Støttefond.

Fonden, der blev stiftet i 1980, har til formål at yde støtte til personer, der er ramt af blødersygdom, udbredelse af kendskab til blødersygdomme samt forskning, herunder rejselegater, kontakt til udenlandske organisationer og lignende.

Det er ikke et krav for ansøgning, at man er medlem af foreningen. Efter ansøgning har fonden blandt andet ydet tilskud til rejseforsikringer og udgifter i forbindelse med studieophold og rejser, tilskud læger og sygeplejerskers forskning og deltagelse i fagligt relevante konferencer, tilskud til fodtøj, der støtter og skåner fod- og ankelled, støtte til motion fx cykel, m.m. Læs mere om ansøgningsprocedure på foreningens hjemmeside: https://www.bloderforeningen.dk/om-foreningen/fonde-og-legater/forsknings-ogstottefonden/Fonden drives af en frivillig bestyrelse, der både tæller medlemmer udpeget af Danmarks Bløderforening og eksterne repræsentanter:

- Daniel Straagaard Jensen Formand (Danmarks Bløderforening)
- Christian Krog Madsen Kasserer (Danmarks Bløderforening)
- Poul Arnø (Danmarks Bløderforening)
- Irene Jensen (Scleroseforeningen)
- Inger Borregaard (Hæmofilicenter Rigshospitalet)

Der søges om støtte fra medicinalfirmaer, der har bløderrelaterede produkter på det danske marked. Der søges i 2022 om 4.000 kr. pr. firma. Foreningen vil i medlemsbladet Blødernyt, der udkommer to gange årligt, takke de firmaer, der støtter Forsknings- og Støttefonden og efter aftale trykke firmaernes logo.

Støtten modtages med tak. Kontakt mig gerne, hvis der er spørgsmål til ansøgningen.

Venlig hilsen Karen Binger Holm

Sekretariatsleder

# **SCHEDULE 2**

# **BENEFITS OF THE SPONSORSHIP**

Sobi logo twice yearly (during 2022) in Blødernyt – all companies supporting the funding will get their name and logo in the magazine.